Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
HKD 12.66
(0.48%)
HKD 12.66
(0.48%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.5 Billion CNY | 3.38% |
| 2022 | 1.45 Billion CNY | -63.89% |
| 2021 | 4.02 Billion CNY | 152.36% |
| 2020 | 1.59 Billion CNY | 105.77% |
| 2019 | 775.08 Million CNY | 82885.97% |
| 2018 | 934 Thousand CNY | -18.64% |
| 2017 | 1.14 Million CNY | -69.44% |
| 2016 | 3.75 Million CNY | 30.14% |
| 2015 | 2.88 Million CNY | -50.24% |
| 2014 | 5.8 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 405.25 Million CNY | 6.42% |
| 2024 Q1 | 380.8 Million CNY | -26.21% |
| 2023 FY | 1.5 Billion CNY | 3.38% |
| 2023 Q1 | 255.15 Million CNY | -82.45% |
| 2023 Q3 | -669.7 Million CNY | -261.55% |
| 2023 Q4 | 516.09 Million CNY | 177.06% |
| 2023 Q2 | 414.54 Million CNY | 62.47% |
| 2022 Q3 | -946.04 Million CNY | -398.88% |
| 2022 Q1 | 629.51 Million CNY | -51.81% |
| 2022 FY | 1.45 Billion CNY | -63.89% |
| 2022 Q4 | 1.45 Billion CNY | 253.64% |
| 2022 Q2 | 316.52 Million CNY | -49.72% |
| 2021 Q3 | 603.94 Million CNY | 20.95% |
| 2021 Q4 | 1.3 Billion CNY | 116.32% |
| 2021 Q1 | 1.61 Billion CNY | 176.58% |
| 2021 Q2 | 499.33 Million CNY | -69.08% |
| 2021 FY | 4.02 Billion CNY | 152.36% |
| 2020 Q2 | 402.89 Million CNY | 134.19% |
| 2020 FY | 1.59 Billion CNY | 105.77% |
| 2020 Q4 | 583.96 Million CNY | 33.94% |
| 2020 Q3 | 435.99 Million CNY | 8.22% |
| 2020 Q1 | 172.03 Million CNY | -30.62% |
| 2019 Q1 | 79.07 Million CNY | -59.19% |
| 2019 Q4 | 247.96 Million CNY | 13.84% |
| 2019 Q3 | 217.81 Million CNY | -5.39% |
| 2019 Q2 | 230.23 Million CNY | 191.15% |
| 2019 FY | 775.08 Million CNY | 82885.97% |
| 2018 Q1 | 1.46 Million CNY | 527.22% |
| 2018 Q3 | - CNY | -100.0% |
| 2018 FY | 934 Thousand CNY | -18.64% |
| 2018 Q2 | 233.5 Thousand CNY | -84.06% |
| 2018 Q4 | 193.77 Million CNY | 0.0% |
| 2017 FY | 1.14 Million CNY | -69.44% |
| 2017 Q3 | - CNY | 100.0% |
| 2017 Q4 | 233.5 Thousand CNY | 0.0% |
| 2017 Q2 | -1.44 Million CNY | -155.78% |
| 2017 Q1 | 2.59 Million CNY | 241.28% |
| 2016 FY | 3.75 Million CNY | 30.14% |
| 2016 Q1 | 26.68 Thousand CNY | -97.17% |
| 2016 Q4 | 760.77 Thousand CNY | -74.15% |
| 2016 Q3 | 2.94 Million CNY | 10926.84% |
| 2016 Q2 | 26.68 Thousand CNY | -0.0% |
| 2015 Q4 | 943.39 Thousand CNY | 0.0% |
| 2015 Q2 | 499.99 Thousand CNY | -0.0% |
| 2015 Q1 | 500 Thousand CNY | -82.55% |
| 2015 FY | 2.88 Million CNY | -50.24% |
| 2015 Q3 | 943.39 Thousand CNY | 88.68% |
| 2014 Q3 | 2.86 Million CNY | 8000.08% |
| 2014 FY | 5.8 Million CNY | 0.0% |
| 2014 Q2 | 35.37 Thousand CNY | 0.0% |
| 2014 Q1 | 35.37 Thousand CNY | 0.0% |
| 2014 Q4 | 2.86 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 484.71 Million HKD | -209.984% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 71.771% |